Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis

[1]  D. Arnold,et al.  Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study , 2022, Advances in Therapy.

[2]  D. Arnold,et al.  Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results , 2021, Multiple sclerosis.

[3]  Jason P. Mendoza,et al.  Multiple Sclerosis Patients Treated With Diroximel Fumarate in the Real-World Setting Have High Rates of Persistence and Adherence , 2021, Neurology and Therapy.

[4]  M. Trojano,et al.  Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network , 2021, Frontiers in Neurology.

[5]  R. Gold,et al.  Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study , 2021, Therapeutic advances in neurological disorders.

[6]  V. Meca-Lallana,et al.  Three-Year Effectiveness of Dimethyl Fumarate in Multiple Sclerosis: A Prospective Multicenter Real-World Study , 2020, CNS Drugs.

[7]  R. Edwards,et al.  Real-world adherence to, and persistence with, once- and twice-daily oral disease-modifying drugs in patients with multiple sclerosis: a systematic review and meta-analysis , 2020, BMC Neurology.

[8]  W. Vargas,et al.  Real-World Safety and Effectiveness of Dimethyl Fumarate in Hispanic or Latino Patients with Multiple Sclerosis: 3-Year Results from ESTEEM , 2020, Neurology and Therapy.

[9]  D. Okuda,et al.  Real-World Safety and Effectiveness of Dimethyl Fumarate in Black or African American Patients with Multiple Sclerosis: 3-Year Results from ESTEEM , 2020, Neurology and Therapy.

[10]  M. Freedman,et al.  Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study , 2020, CNS Drugs.

[11]  D. Arnold,et al.  Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years’ follow-up of DEFINE, CONFIRM, and ENDORSE , 2020, Therapeutic advances in neurological disorders.

[12]  D. Arnold,et al.  Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study , 2019, Multiple sclerosis.

[13]  Michael J. Palte,et al.  Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study , 2019, Advances in Therapy.

[14]  H. Hartung,et al.  Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm , 2019, Current opinion in neurology.

[15]  S. Peiró,et al.  Improving the accuracy of medication adherence measures using linked prescription and dispensation data: findings from the ESOSVAL cohort of patients treated with osteoporosis drugs , 2019, Current medical research and opinion.

[16]  J. Sloane,et al.  Real-World Characterization of Dimethyl Fumarate-Related Gastrointestinal Events in Multiple Sclerosis: Management Strategies to Improve Persistence on Treatment and Patient Outcomes , 2019, Neurology and Therapy.

[17]  P. Repovic,et al.  Effectiveness of Delayed-release Dimethyl Fumarate on Clinical and Patient-reported Outcomes in Patients With Relapsing Multiple Sclerosis Switching From Glatiramer Acetate: RESPOND, a Prospective Observational Study. , 2018, Clinical therapeutics.

[18]  D. Centonze,et al.  Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study , 2018, CNS Drugs.

[19]  M. Rovaris,et al.  Two-year real-life efficacy, tolerability and safety of dimethyl fumarate in an Italian multicentre study , 2018, Journal of Neurology.

[20]  P. Duquette,et al.  The impact of treatment adherence on clinical and economic outcomes in multiple sclerosis: Real world evidence from Alberta, Canada. , 2017, Multiple sclerosis and related disorders.

[21]  P. Rasmussen,et al.  The impact of quality of life on treatment preferences in multiple sclerosis patients , 2017, Patient preference and adherence.

[22]  V. Herrera,et al.  Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year. , 2017, Journal of managed care & specialty pharmacy.

[23]  A. Boster,et al.  Comparative Effectiveness Research of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of a Large Health Insurance Claims Database , 2017, Neurology and Therapy.

[24]  R. Sobel,et al.  Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2 , 2016, Proceedings of the National Academy of Sciences.

[25]  T. Vollmer,et al.  Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: Two-year experience , 2017, Multiple sclerosis journal - experimental, translational and clinical.

[26]  R. Gold,et al.  Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl Fumarate. , 2015, International journal of MS care.

[27]  D. Centonze,et al.  Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS , 2015, Acta Neuropathologica.

[28]  J. Poveda,et al.  Treatment adherence and other patient-reported outcomes as cost determinants in multiple sclerosis: a review of the literature , 2014, Patient preference and adherence.

[29]  J. Köhl,et al.  Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate's protective effect in EAE. , 2014, The Journal of clinical investigation.

[30]  David H. Miller,et al.  Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. , 2012, The New England journal of medicine.

[31]  Bradley C Martin,et al.  Good and poor adherence: optimal cut-point for adherence measures using administrative claims data , 2009, Current medical research and opinion.

[32]  J. S. Butler,et al.  Factors leading patients to discontinue multiple sclerosis therapies. , 2005, Journal of the American Pharmacists Association : JAPhA.

[33]  N. Chavannes,et al.  Investigating the association between medication adherence and health-related quality of life in COPD: Methodological challenges when using a proxy measure of adherence. , 2016, Respiratory medicine.

[34]  J. Chataway,et al.  Multiple sclerosis, a treatable disease. , 2016, Clinical medicine.

[35]  J. Menzin,et al.  Narrative Review of the Literature on Adherence to Disease-Modifying Therapies Among Patients with Multiple Sclerosis , 2013, Journal of managed care pharmacy : JMCP.

[36]  J. Stephenson,et al.  Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis , 2011, Advances in therapy.